Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The worldwide incidence of multidrug-resistant tuberculosis (MDR-TB) is rapidly increasing, and it has emerged as a pressing public health issue in Iran. Nevertheless, there is a scarcity of up-to-date research on the prevalence of MDR-TB in individuals with pulmonary TB in the country. In this cross-sectional study, we gathered a total of 1216 respiratory samples, each corresponding to a unique patient, from five distinct regional TB laboratories in Iran. We identified clinical isolates as Mycobacterium tuberculosis using the IS6110-based polymerase chain reaction assay and Xpert MTB/RIF. Drug susceptibility testing (DST) was conducted using the conventional proportion method. Out of the collected specimens, 448 tested positive for M. tuberculosis. Among these isolates, 445 (99.4%) exhibited susceptibility to the tested drugs, while 3 (0.6%) were found to be MDR. The findings from this recent study indicate that the prevalence of MDR in Iran stands at 0.6%. The absence of recently approved treatment protocols in various regions of Iran, along with inadequately equipped laboratories lacking DST capabilities, could contribute significantly to the rise in TB/MDR-TB prevalence in Iran. Therefore, the implementation of enhanced treatment management strategies and the adoption of innovative technologies are essential steps toward improving the current situation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4081/monaldi.2024.2844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and factors influencing drug-resistant tuberculosis in four regions of Ghana.
PLoS One
September 2025
University of Health and Allied Sciences, Volta Region-Ho, Ghana.
Introduction: The alarming rate of drug-resistant tuberculosis (DR-TB) globally is a threat to treatment success among positive tuberculosis (TB) cases. Studies aimed at determining the prevalence, trend of DR-TB and socio-demographic and clinical risk factors contributing to DR-TB in the four regions of Ghana are currently unknown. This study sought to determine the prevalence and trend of DR-TB, identify socio-demographic and clinical risk factors that influence DR-TB, and analyse the relationship between underweight and adverse drug reactions and treatment outcomes among DR-TB patients in four regions of Ghana.
View Article and Find Full Text PDFHost-directed immunotherapy to enhance treatment of Mycobacterium tuberculosis infection.
Int Immunopharmacol
September 2025
Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, School of Life Science and Technology, Shandong Second Medical University, PR China. Electronic address:
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains one of the leading causes of morbidity and mortality worldwide, particularly in low- and middle-income countries. The extensive use of antibiotics has led to the emergence of multidrug-resistant and extensively drug-resistant MTB strains, intensifying the challenges associated with TB treatment. In this context, host-directed immunotherapy has emerged as a promising adjunct strategy that aims to modulate the host immune response rather than directly targeting the pathogen.
View Article and Find Full Text PDFScreen first, vaccinate later: Enhancing tuberculosis vaccination safety through newborn immunodeficiency screening.
Vaccine
September 2025
Hospital for Gynaecology and Obstetrics Kranj, Kidričeva cesta 38a, 4000 Kranj, Slovenia.
Tuberculosis (TB) remains a global health challenge, with around 10 million new cases reported annually and multidrug-resistant strains complicating control efforts. Although incidence has declined in many high-income regions, neonatal populations remain vulnerable, underscoring the continued role of Bacillus Calmette-Guérin (BCG) vaccination. BCG vaccination provides strong protection against severe forms of TB in infancy, though its efficacy against pulmonary disease in adolescents and adults is modest.
View Article and Find Full Text PDFStrengthening pathogen and antimicrobial resistance surveillance through environmental monitoring in sub-Saharan Africa: stakeholder perspectives.
Int J Hyg Environ Health
September 2025
Microbiology Unit, Finnish Institute for Health, and Welfare, Neulaniementie 4, 70701, Kuopio, Finland; Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Agnes Sjöbergin katu 2, 00014, Helsinki, Finland. Electronic address: tarja.pitkanen@t
Wastewater and environmental surveillance (WES) is an emerging tool for monitoring emergence and trends of waterborne, respiratory, and antimicrobial-resistant (AMR) pathogens. In many developing countries with limited pathogen surveillance systems, WES can complement and support existing monitoring efforts and strengthen pathogen surveillance capacity. This study explored priority pathogens for WES and assessed existing surveillance practices, including WES, in Tanzania, Burkina Faso, and the Democratic Republic of the Congo (DRC).
View Article and Find Full Text PDFDiagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing?
J Clin Microbiol
September 2025
The Johns Hopkins Medical SystemsBaltimore, Maryland, USA.
Rapid diagnosis of resistance-conferring mutations to antibiotics used for the treatment of tuberculosis (TB) is critical for patient care and public health control efforts. Prior guidelines included the use of fluoroquinolones (FQs) for the treatment of drug-resistant TB, including multidrug-resistant TB, pre-extensively drug-resistant TB, and extensively drug-resistant TB. More recently, a short-course regimen for antibiotic-susceptible TB was introduced, which includes the use of a FQ, a drug class that diagnostic algorithms in the United States (US) typically do not test for if all first-line agents are susceptible.
View Article and Find Full Text PDF